



September 13, 2017

✓ **BSE Limited,**

Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

The National Stock Exchange of India Ltd.,

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015.

Enclosed is a Press Release as regards receipt of final US FDA approval for Metronidazole Tablets USP, 250 mg and 500 mg, to market a generic version of G.D. Searle LLC's Flagyl® Tablets, 250 mg and 500 mg.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

Yours faithfully,

For **LUPIN LIMITED**

R. V. SATAM
COMPANY SECRETARY

Encl.: a.a.



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

Lupin receives FDA approval for generic Flagyl® Tablets

Mumbai, September 13, 2017: Pharma Major Lupin announced that it has received final approval for its Metronidazole Tablets USP, 250 mg and 500 mg from the United States Food and Drug Administration (FDA) to market a generic version of G.D. Searle LLC's Flagyl® Tablets, 250 mg and 500 mg.

Lupin's Metronidazole Tablets USP, 250 mg and 500 mg are the AB rated generic equivalent of G.D. Searle LLC's Flagyl® Tablets, 250 mg and 500 mg. It is indicated in the treatment of wide variety of infections which are caused by particular types of bacteria and other infectious organisms.

Flagyl® Tablets had US sales of USD 44.1 million (IMS MAT June 2017).

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 7th and 6th largest generics pharmaceutical company by market capitalization (June 30th, 2017, Bloomberg) and revenues (March 31st, 2017, Bloomberg) respectively. The Company is the 4th largest pharmaceutical player in the US by prescriptions (Quintiles IMS MAT March 2017); 2nd largest Indian pharmaceutical company by global revenues (March 31st, 2017, Bloomberg); 6th largest generic pharmaceutical player in Japan and 6th largest company in Indian Pharmaceutical Market (Quintiles IMS MAT June 2017).

For the financial year ended 31st March, 2017, Lupin's Consolidated sales and Net profit stood at Rs. 171,198 million (USD 2.55 billion) and Rs. 25,575 million (USD 381 million) respectively. Please visit <http://www.lupin.com> for more information. You could also follow us on Twitter - www.twitter.com/lupinlimited

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –

Pooja Thakran

VP – Corporate Communications

Email: poojathakran@lupin.com

Ph: +91-22-66402531 / 8291013225

Arvind Bothra

Head – Investor Relations and M&A

Email: arvindbothra@lupin.com

Ph: +91-22-66402137

**Safe Harbor Statement*

Flagyl® is a registered trademark of G.D. Searle LLC.